If you’ve been researching outsourced drug manufacturing, you’ve probably come across the term CDMO more than a few times. It gets thrown around a lot, sometimes without much explanation. So before getting into which companies are doing it well, it helps to understand what the term actually means and why India specifically has become such a significant player in this space.
What Exactly Is a CDMO?
A CDMO, or Contract Development and Manufacturing Organization, is a company that handles both the development and manufacturing of pharmaceutical products on behalf of another company. This is slightly different from a CMO, which typically handles only the manufacturing side.
When a pharma brand brings a new drug to market, they don’t always have the facilities, regulatory expertise, or capacity to do everything in-house. That’s where a CDMO steps in. They take on the science, the production, and often the compliance paperwork too, allowing the drug originator to focus on research, sales, and distribution.
For oncology in particular, this partnership model has become almost essential. Cancer drugs are complex to formulate, highly potent, and demand strict containment standards. Building that infrastructure from scratch costs enormous amounts of money and time. Outsourcing to a specialized oncology CDMO makes practical and financial sense for most pharma companies.
Why India Has Become a Go-To Destination
Ten years ago, most global pharma companies outsourcing their manufacturing were looking primarily at China. That’s changed significantly. The “China+1” strategy, driven by both supply chain concerns and geopolitical caution, has pushed many multinationals to diversify. India has been the biggest beneficiary of this shift.
It’s not just about cost, though India’s cost advantage is real. Drug development here runs somewhere between 30 to 40% cheaper than in Western countries. But cost alone doesn’t explain why top-tier global brands trust Indian facilities with life-saving drugs.
A few things stand out:
India produces a massive pool of pharmaceutical scientists and engineers every year. The country is also one of the world’s largest producers of Active Pharmaceutical Ingredients, meaning the raw material supply chain is already established. And critically, several Indian facilities now hold approvals from USFDA, EMA, MHRA, TGA, and other stringent regulatory bodies. That’s not easy to get. It signals a serious, sustained commitment to quality.
Government support through Production Linked Incentive (PLI) schemes has further accelerated investments in infrastructure and R&D. The result is an ecosystem that’s genuinely competitive on a global scale.
The Range of Services CDMO Companies in India Offer
Not all CDMO companies in India offer the same scope. Some specialize in early-stage development and clinical supply. Others focus on commercial-scale manufacturing. The best ones offer the full spectrum.
Common service areas include:
Drug formulation and development – this is the initial stage where the drug’s physical form (tablet, capsule, injectable) is designed and optimized for stability, bioavailability, and patient use.
Clinical trial material production – small batches made under strict GMP conditions for Phase I, II, and III trials.
Commercial manufacturing – large-scale production once the drug has regulatory approval and is ready for the market.
Regulatory support – filing assistance for USFDA, EMA, DCGI, and other regulatory bodies, including IND, ANDA, and NDA documentation.
Packaging and serialization – compliant labeling, cold chain handling, and global distribution logistics.
For oncology specifically, there’s an additional layer of complexity. High-Potency APIs, or HPAPIs, require specialized containment suites. Manufacturing targeted therapies, kinase inhibitors, or immunotherapy components demands a different infrastructure than, say, producing a common antibiotic. Only certain Indian CDMOs have invested in building these capabilities, which is why choosing the right partner matters.
A Look at the CDMO Landscape in India
The sector has several well-known names. Syngene International, based out of Bengaluru, has been around since 1993 and operates across the full drug development lifecycle. Piramal Pharma Solutions is a global name with deep end-to-end capabilities. Divi’s Laboratories has built a strong position in custom API synthesis. Sai Life Sciences, Aragen, and Neuland Laboratories are other established players in the R&D and manufacturing space.
Within the oncology segment specifically, there are more focused players. These are CDMOs that have made oncology their core business rather than treating it as one category among many. The advantage of working with an oncology-specialized partner is depth. They understand the containment protocols, the regulatory complexity, and the formulation challenges specific to cancer drugs.
What to Look For When Choosing a Partner
If you’re evaluating CDMO companies in India for a specific program, a few things are worth checking closely.
Regulatory track record. Does the facility have active approvals from the markets you’re targeting? USFDA approval, for example, isn’t something a company earns once and keeps forever. It requires ongoing compliance.
Therapeutic area experience. A CDMO that has manufactured oncology drugs for years will handle your molecule differently than one doing it for the first time.
Containment capability. For HPAPIs and high-potency compounds, ask specifically about their OEB (Occupational Exposure Banding) ratings. OEB-4 and OEB-5 capabilities are not universal.
Scale flexibility. Your needs will change as your drug progresses from clinical to commercial stages. Can the CDMO scale with you?
Communication and transparency. This sounds soft but it matters enormously in practice. Delays, deviations, and changes happen in manufacturing. How a partner handles those situations tells you more than any audit.
The Oncology CDMO Segment Is Growing for a Reason
Global oncology drug demand is on a trajectory that isn’t slowing down. Cancer cases are rising, treatment options are expanding, and the complexity of new therapies – from targeted small molecules to biosimilars to RNA-based treatments – means manufacturing demands are becoming more specialized, not less.
Indian CDMOs are responding to this by upgrading infrastructure, adopting automation, and building high-containment suites that can handle the next generation of cancer drugs. A few are already preparing capabilities for cell and gene therapies and radiopharmaceuticals, which represent the frontier of oncology treatment.
For global pharma companies looking to move quickly, reduce costs, and maintain quality – partnering with a well-credentialed Indian CDMO is increasingly not just an option but a strategic priority.
FAQs
What is the difference between a CDMO and a CMO?
A CMO, or Contract Manufacturing Organization, handles only the production side of drug development. A CDMO goes further – it covers both development (formulation design, process development, clinical trial supply) and manufacturing. CDMOs are more involved from the early stages of a drug’s journey.
Why do global pharma companies prefer CDMO companies in India?
India offers a combination that’s hard to find elsewhere – cost efficiency, a large pool of trained pharmaceutical scientists, one of the world’s biggest API supply chains, and an increasing number of facilities approved by stringent regulators like USFDA and EMA. The government’s PLI schemes have also accelerated infrastructure investments significantly.
Are Indian CDMOs equipped to manufacture oncology drugs?
Yes, several Indian CDMOs have built specialized facilities for oncology manufacturing, including high-containment suites for High-Potency Active Pharmaceutical Ingredients. They comply with international standards and supply cancer medicines to regulated markets across the US, Europe, and beyond.
What is an oncology CDMO?
An oncology CDMO specializes in the development and manufacturing of cancer drugs. These compounds are often highly potent and require specialized containment, formulation expertise, and strict quality controls. Working with an oncology-specific CDMO typically results in better outcomes than a generalist partner.
How do I choose the right CDMO in India for my program?
Start with regulatory credentials relevant to your target markets. Then look at their experience in your specific therapeutic area, their containment capabilities for high-potency molecules, their ability to scale production, and their track record of on-time delivery and transparent communication with partners.
What types of oncology drugs can Indian CDMOs manufacture?
Indian CDMOs work across a broad range of cancer drug categories – oral solid dosage forms like tablets and capsules (including cytotoxic drugs and targeted therapies), injectable chemotherapeutics, biosimilars, and increasingly, next-generation modalities like biologics and immunotherapies.
